Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KINETA, INC./DEPTI · Entity 77778 | Director | June 29, 2020 | July 01, 2020 |
| Savara IncSVRA · Entity 4900 | CHIEF MEDICAL OFFICER | December 14, 2021 | December 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KINETA, INC./DE
Report date June 29, 2020 · Filed July 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2030-06-29 | Direct | 17,400 |
Reported balance
After 2020-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-29 · Grant · Acquired 17,400 · Balance 17,400 F1: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer.
Savara Inc
Report date December 14, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 300,000 |
Reported balance
After 2021-12-14 transaction · row 1
1 source rowRow 1 · 2021-12-14 · Grant · Acquired 125,000 · Balance 300,000 F1: Represents restricted stock units ("RSUs") that vest in full on December 14, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2031-12-14 | Direct | 100,000 |
Reported balance
After 2021-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-14 · Grant · Acquired 100,000 · Balance 100,000 F2: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2021, subject to the reporting person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that vest in full on December 14, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2021, subject to the reporting person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2021 Filed Dec 14, 2021 23:26 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-069579 · doc4.xml · derivative · entry 2 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-14 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2021, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 23:26 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069579 · doc4.xml · nonDerivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 09, 2021 Filed Dec 9, 2021 15:59 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 25,000 | $1.05 | $26,250.00 |
DisclosureSEC source: 0001209191-21-068649 · doc4.xml · nonDerivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Read SEC document |
| May 17, 2021 Filed May 18, 2021 01:57 UTC | Savara Inc SVRA · Entity 4900 | SaleCommon Stock | 50,000 | $1.56 | $77,870.00 |
DisclosureSEC source: 0001209191-21-033362 · doc4.xml · nonDerivative · entry 2 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020 in order to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 15, 2021. F2 · price: The price is a weighted average sale price. The sale prices ranged from $1.50 to $1.61. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 15, 2021 Filed May 18, 2021 01:57 UTC | Savara Inc SVRA · Entity 4900 | Exercise / conversionRestricted Stock Units · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033362 · doc4.xml · derivative · entry 3 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vested in full on May 15, 2021. F3 · derivative.expiration_date: The restricted stock units vested in full on May 15, 2021. Read SEC document |
| May 15, 2021 Filed May 18, 2021 01:57 UTC | Savara Inc SVRA · Entity 4900 | Exercise / conversionCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033362 · doc4.xml · nonDerivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 17:35 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-20-063982 · doc4.xml · derivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 16, 2020, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:29 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 17,400 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-20-039825 · doc4.xml · derivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 Underlying: Common Stock · 17,400 shares Expires 2030-06-29 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:10 UTC | Savara Inc SVRA · Entity 4900 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028226 · doc4.xml · derivative · entry 2 Chowdhury Badrul A. · CIK 0001776662 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full on the eighteen (18) month anniversary of November 15, 2019, subject to the reporting person's continued service with the Issuer. Vested shares will be delivered to the reporting person on the first date that is administratively practicable following the date on which such unit becomes vested. F3 · derivative.expiration_date: The restricted stock units shall vest in full on the eighteen (18) month anniversary of November 15, 2019, subject to the reporting person's continued service with the Issuer. Vested shares will be delivered to the reporting person on the first date that is administratively practicable following the date on which such unit becomes vested. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:10 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000899243-19-028226 · doc4.xml · derivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-11-26 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in sixteen equal installments on each quarterly anniversary of November 15, 2019, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 12, 2019 Filed May 14, 2019 17:11 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 30,600 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001209191-19-029710 · doc4.xml · derivative · entry 1 Chowdhury Badrul A. · CIK 0001776662 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Underlying: Common Stock · 30,600 shares Expires 2029-05-12 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on August 12, 2019 until the option is fully vested and exercisable on May 12, 2020, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.